Treatment of Patients with Melanoma of the Extremity Using Hyperthermic Isolated Limb Perfusion with Melphalan, Tumor Necrosis Factor, and Interferon Gamma: Results of a Tumor Necrosis Factor Dose-Escalation Study

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 479-489

  Fraker, Douglas L ^a   Alexander, H Richard ^b   Andrich, Mary ^b   Rosenberg, Steven A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; EDEMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIC THERAPY; LIMB PERFUSION; MALE; MELANOMA; MYOPATHY; NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REGIONAL PERFUSION; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HUMANS; INTERFERON TYPE II; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; RECOMBINANT PROTEINS; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030058843     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.479     Document Type: Article

References (19)

1. Creech O, Krementz ET, Ryan RF, et al: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 148:616-632, 1958
2. Luck JM: Action of p-dichloroethyl amino-L-phenylalanine on Harding-Passey mouse melanoma. Science 123:984-985, 1956
3. Stehlin JS: Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 129:305-308, 1969
4. Cumberlin R, DeMoss E, Lassus M, et al: Isolation perfusion for malignant melanoma of the extremity: A review. J Clin Oncol 3:1022-1031, 1985
5. Lejeune FJ, Lienard D, Douaihy ME, et al: Results of 206 isolated limb perfusions for malignant melanoma. Eur J Cancer Clin Oncol 15:510-519, 1989
6. Thompson JF, Gianoutsos MP: Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 16:227-233, 1992
7. Martijn H, Oldhoff J, Koops HS: Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities. J Surg Oncol 20:9-13, 1982
8. Lienard D, Lejeune F, Ewalenko I: In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16:234-240, 1992
9. Klaase JM, Kroon BBR, van Geel AN, et al: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion using melphalan. Surgery 115:39-45, 1994
10. Lienard D, Ewalenko P, Delmotti JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60, 1992
11. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
12. Thom AK Alexander HR, Andrich MP, et al: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol 13:264-273, 1995
13. Gérain J, Liénard D, Ewalenko P, et al: High serum levels of the TNF-α after its administration for isolation perfusion of the limb. Cytokine 4:585-591, 1992
14. Fraker, DL, Alexander, HR and Pass, HI: Biologic therapy with TNF: Systemic administration and isolation-perfusion, in, Biologic Therapy of Cancer. DeVita V, Hellman S, Rosenberg SA (eds): Philadelphia, PA, Lippincott, 1995, pp 329-345
15. Fraker DL, Alexander HR: Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma, in, Important Advances in Oncology. DeVita VT, Hellman S, Rosenberg SA (eds): Philadelphia, PA, Lippincott, 1994, pp 179-192
16. Asher A, Mulé JJ, Reichert CM, et al: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963-974, 1987
17. Mulé JJ Asher A, McIntosh J, et al: Antitumor effect of recombinant tumor necrosis factor-α against murine sarcomas at visceral sites: Tumor size influences the response to therapy. Cancer Immunol Immunother 26:202-208, 1988
18. Folli S Pèlegrin A, Chalandon Y, et al: Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 53:829-836, 1993
19. Hill S, Fawcett WJ, Sheldon J, et al: Low-dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80:995-997, 1993